echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Tianjing Bio will announce Uliledlimab's mechanism of action and preclinical research data at the AACR annual meeting

    Tianjing Bio will announce Uliledlimab's mechanism of action and preclinical research data at the AACR annual meeting

    • Last Update: 2021-07-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Tianjing Bio is a biopharmaceutical company in the clinical stage.
    It is committed to the target biological research of innovative biopharmaceuticals, antibody technology, and clinical development and product commercialization in China and the United States.
    It provides new types of cancer treatments in the world with urgent needs.
    Effective treatment

    .
    The company announced today that it will announce the uniqueness of its self-developed and highly differentiated CD73 antibody uliledlimab (also known as TJD5) during the American Society for Cancer Research (AACR) online conference to be held from April 10 to 15, 2021.
    Mechanism of action and related preclinical research data

    .


    Uliledlimab is an innovative CD73 humanized antibody that effectively relieves the immune suppression of the tumor microenvironment by inhibiting the production of adenosine to improve the systemic and local tumor immune response

    .
    The molecular differentiation advantage of Uliledlimab lies in its unique pharmacological mechanism of action, that is, by recognizing a unique epitope, and completely inhibiting the activity of CD73 in an "endo-dimer" binding mode, so as to achieve superior anti-tumor effects

    .
    This feature solves the problem of the "hook effect" that is common in other CD73 antibodies with a dose-effect deviation

    .
    The company will focus on displaying the new protein structure of uliledlimab binding to CD73, as well as a series of preclinical data on inhibition of enzyme activity, immunomodulation and anti-tumor activity when its single agent and PD-(L)1 antibody are used in combination

    .
    The research results announced this time further validate the differentiated advantages of uliledlimab and help to rapidly advance its clinical research and development

    .

    The poster details are as follows:

    title

     

    Preclinical characterization of uliledlimab, a differentiated CD73 blocking antibody with
    a unique intra-dimer binding mechanism for cancer immunotherapy

    Abstract number

    1871

    Reporter

    Dr.
    Zhengyi Wang, Vice President of Tianjing Bio-Drug Discovery


    At present, bio-day environment has been completed uliledlimab monotherapy with import and A (Tai Shengqi teplizumab
    ® ) clinical study a combination therapy of solid tumors of the United States, and has submitted plans to the American Society of Clinical Oncology material in 2021 ( The detailed data of the clinical study will be announced at the ASCO annual meeting
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.